WINNIPEG, Manitoba - (January 31, 2003) - Medicure Inc.
(TSX: MPH), a cardiovascular biotechnology company, was pleased
to host a special gathering for members of the Winnipeg investment
community yesterday to celebrate the positive results from the MEND-1
Phase II trial.
With the promising results from the recently completed MEND-1 Phase
II trial, Dr. Friesen added that, "we are very keen to move
quickly toward proceeding with additional Phase II trials and then
on to Phase III. In fact, at a meeting with the FDA, they strongly
supported us carrying on a Phase II/III. So we're very encouraged
to proceed aggressively, not only to the bypass, but also to acute
MI or acute heart attack studies, and stroke trial and we are well
positioned financially to continue on the current Phase II track."
Commenting on suggestions and inferences that Medicure is actively
seeking new financing options, Chairman, President and CEO, Albert
D. Friesen, Ph.D., stated emphatically: "This is absolutely
not correct. As at November 30, 2002, the end of our second quarter,
the Company reported a solid cash position and cash equivalents
totaling approximately $5.7 million. As such, we have sufficient
capital to undertake a further Phase II study that we've planned
all along - the bypass and stroke Phase II study."
In addition, Dr. Friesen stated that the interest level from potential
partners has increased since the Company announced the positive
results from the MEND-1 trial. "We are in discussions with
several large pharmaceutical companies regarding potential partnership
opportunities for our Phase III trial and we hope to make an announcement
on this later this year," he said.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine including the prevention
and treatment of ischemia, ischemic reperfusion injury, and stroke.
This press release contains forward-looking statements that involve
risks, which may cause actual results to differ materially from
the statements made, and accordingly may be deemed to be forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking statements
are made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For additional information contact:
Derek Reimer
Chief Financial Officer
Medicure Inc.
Tel. 204-487-7412
Fax 204-488-9823
info@medicure.com
Back to 2003 News Archives
